Case study

Gene expression biomarkers in osteoarthritis

The Challenge

The client developed a cartilage‑on‑a‑chip technology and a gene panel to monitor treatment effects. They needed additional in vivo human evidence and comprehensive literature review to refine the panel and convince investors.

Our Approach

We reviewed evidence, collected datasets and synthesised insights to refine an osteoarthritis gene panel.

  • Evidence review & gap analysis: Worked with the client to assess existing evidence, summarise pathways and identify conflicts, creating structured overviews and compiling gene‑expression data.
  • Data collection & hypothesis generation: Conducted exhaustive literature reviews and gathered relevant gene‑expression datasets to support future analyses.
  • Insight synthesis: Analysed complexities across models, disease stages and anatomical regions to produce a list of differentially regulated genes.

The Outcome

  • Provided structured summaries with annotated extracts and a table of evidence.
  • Delivered detailed context for selected markers and a curated data set for future analyses.
  • Identified knowledge gaps and highlighted important differences across models and disease stages.

Why It Matters

Thorough literature synthesis and data curation refine biomarker panels and reveal missing knowledge. This work equips researchers and investors with a clear roadmap for future experiments.

Let’s discuss how we can turn your data into real scientific impact.

Contact us >

Beyond animal testing in drug development

Beyond animal testing in drug development

For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.